Oncolytics Biotech is conducting clinical trials in multiple indications with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program comprises human trials using REOLYSIN® both alone and in combination with chemotherapy, radiotherapy and/or a checkpoint inhibitor, delivered via local and/or intravenous administration.
|Trial Number||Phase||Trial Name||Indication||Location||Status|
||Phase II||Intravenous Administration of REOLYSIN® in Combination with FOLFOX-6 and Bevacizumab (Avastin®) in Patients with Advanced or Metastatic Colorectal Cancer||Colorectal Cancer||
||Phase I||Intravenous Administration of REOLYSIN® in Combination with FOLFIRI and Bevacizumab (Avastin®) in FOLFIRI-Naïve Patients with Mutant Metastatic Colorectal Cancer||Colorectal Cancer||
||Translational||Intravenous Administration of REOLYSIN® Monotherapy for Patients with Metastatic Colorectal Cancer||Colorectal Cancer||
REOLYSIN® is currently available in a clinical trial setting only. It has not been approved in any jurisdiction and is not available for purchase. The Company, its directors, officers, employees and affiliates have no influence over the inclusion of a patient in a clinical trial. Should a patient’s physician determine that he or she may be a suitable clinical trial candidate, they must contact a participating center. Contact information, as well as inclusion and exclusion criteria, for both US and international participating centers can be found at www.clinicaltrials.gov for studies with a US component.